New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 15, 2014
07:55 EDTVTLVital Therapies price target raised to $35 from $20 at Canaccord
Canaccord raised its price target on Vital Therapies to $35 from $20 based on the probability of the success of its Alcohol Induced Liver Disease drug and its substantial market opportunity. Canaccord maintains its Buy rating on Vital Therapies.
News For VTL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
16:09 EDTVTLVital Therapies files to sell 2.5M shares of common stock
BofA Merrill Lynch is acting as sole book-running manager for the offering. William Blair is acting as lead manager and Canaccord Genuity and SunTrust Robinson Humphrey are acting as co-managers for the offering.
September 22, 2014
06:15 EDTVTLVital Therapies files to sell $46M in common stock
BofA/Merrill is acting as lead book running manager for the offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use